Use of NK-1 receptor antagonists for treating movement disorders

ABSTRACT

The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 antagonist for the manufacture of a medicament for oral administration for the treatment or prevention of movement disorders, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Ser. No. 08/980,931,filed Dec. 1, 1997, now U.S. Pat. No. 5,925,627.

This invention relates to the treatment or prevention of movementdisorders by the administration of a specific class of NK-1 receptorantagonists.

Diseases of the extrapyramidal motor systems cause either a loss ofmovement (akinesia) accompanied by an increase in muscle tone (rigidity)or abnormal involuntary movements (dyskinesias) often accompanied by areduction in muscle tone. The akinetic-rigid syndrome calledparkinsonism, and the dyskinesias represent opposite ends of thespectrum of movement disorders (for review see C. D. Marsden in OxfordTextbook of Medicine, 3rd Edition, Oxford University Press, 1996, vol.3, pages 3998-4022).

Treatment of akinetic-rigid conditions such as parkinsonism typicallyinvolves the use of levodopa, anticholinergics or dopamine agonists.Levodopa is converted into dopamine in the brain by the enzyme dopadecarboxylase. However, this enzyme is also present in the gut wall,liver, kidney and cerebral capillaries, thus the peripheral formation oflevodopa metabolites may give rise to side-effects such as nausea,vomiting, cardiac dysrhythmias and postural hypotension. This peripheraldecarboxylation is largely prevented by the addition of a selectiveextracerebral decarboxylase inhibitor, such as carbidopa or benserazide,which themselves do not penetrate the brain. Levodopa combined withcarbidopa (SINEMET™) or benserazide (MADOPAR™) is now the treatment ofchoice when levodopa is indicated. Even then, this combination therapymay be associated with side-effects such as dyskinesias and psychiatricdisturbances.

An anticholinergic such as benzhexol or orphenadrine may be used,however, anticholinergics cause peripheral parasympathetic blockadewhich may cause dry mouth, blurred vision and constipation, and they mayalso precipitate glaucoma, urinary retention and a toxic confusionalstate.

Dopamine agonists such as bromocriptine (PARLODEL™), lisuride andpergolide (CELANCE™) act directly on dopamine receptors and have asimilar side-effect profile to levodopa.

The dyskinesias, notably tremor, chorea, myoclonus, tics and dystonias,are treated with a variety of pharmacological agents. Thus, for example,tremor may be treated with benzodiazepines such as diazepam; chorea maybe treated with diazepam, a phenothiazide or haloperidol, ortetrabenazine; tics may be controlled with neuroleptics such ashaloperidol or pimozide; and dystonias tend to be treated with levodopa,benzodiazepines such as diazepam, anticholinergics such as benzhexol,phenothiazines and other neuroleptics such as haloperidol, andtetrabenazine.

Treatment of psychotic disorders with neuroleptic agents, such ashaloperidol may be at the expense of a number of side-effects, includingextrapyramidal symptoms, acute dystonias, tardive dyskinesias,akathesia, tremor, tachycardia, drowsiness, confusion, posturalhypotension, blurring of vision, precipitation of glaucoma, dry mouth,constipation, urinary hesitance and impaired sexual function.

Neurokinin 1 (NK-1; substance P) receptor antagonists are beingdeveloped for the treatment of a number of physiological disordersassociated with an excess or imbalance of tachykinins, and in particularsubstance P. Examples of conditions in which substance P has beenimplicated include disorders of the central nervous system such asanxiety, depression and psychosis (see, for instance, International(PCT) patent specification Nos. WO 95/16679, WO 95/18124 and WO95/23798).

More recently, International (PCT) patent specification No. WO 96/24353(published Aug. 15, 1996) suggests that a more efficacious and safetreatment of psychiatric disorders would be achieved using a combinationof a tachykinin antagonist and a serotonin agonist or selectiveserotonin reuptake inhibitor (SSRI).

NK-1 receptor antagonists are described in published European PatentSpecification Nos. 0 360 390, 0 394 989, 0 429 366, 0 443 132, 0 482539, 0 512 901, 0 512 902, 0 514 273, 0 514 275, 0 517 589, 0 520 555, 0522 808, 0 528 495, 0 532 456, 0 533 280, 0 536 817, 0 545 478, 0 577394, 0 590 152, 0 599 538, 0 610 793, 0 634 402, 0 686 629, 0 693 489, 0694 535, 0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 714 891, 0 723959, 0 733 632 and 0 776 893; and in International Patent SpecificationNos. 90/05525, 90/05729, 91/09844, 91/18899, 92/01688, 92/06079,92/12151, 92/15585, 92/17449, 92/20661, 92/20676, 92/21677, 93/00330,93/00331, 93/01159, 93/01165, 93/01169, 93/01170, 93/06099, 93/09116,93/10073, 93/14113, 93/18023, 93/19064, 93/21155, 9321181, 93/23380,93/24465, 94/01402, 94/02461, 94/03429, 94/03445, 94/04494, 94/04496,94/05625, 94/07843, 94/10165, 94/10167, 94/10168, 94/10170, 94/11368,94/13639, 94/13663, 94/14767, 94/15903, 94/19320, 94/19323, 94/20500,94/26735, 94/26740, 94/29309, 95/02595, 95/04040, 95/04042, 95/06645,95/07886, 95/07908, 95/08549, 95/11880, 95/14017, 95/15311, 95/16679,95/17382, 95/18124, 95/18129, 95/19344, 95/20575, 95/21819, 96/22525,95/23798, 95/26338, 95/28418, 95/30674, 95/30687, 96/05193, 96/05203,96/06094, 96/07649, 96/10562, 96/16939, 96/18643, 96/20197, 96/21661,96/29304, 96/29317, 96/29326, 96/29328, 96/31214, 96/32385, 96/37489,97/01553, 97/01554, 97/03066, 97/08144, 97/14671, 97/17362, 97/18206,97/19084, 97/19942 and 97/21702; and in British Patent SpecificationNos. 2 266 529, 2 268 931, 2 269 170, 2 269 590, 2 271 774, 2 292 144, 2293 168, 2 293 169, and 2 302 689.

In view of the short-comings of existing therapy, there is a need fornew, safe and effective treatment for movement disorders.

The present invention provides the use of a CNS penetrant NK-1 receptorantagonist in an oral medicament for the treatment of movementdisorders. The compounds of this class advantageously exhibit a rapidonset of action and a reduced side-effect profile when compared againstconventional agents used for the treatment of extrapyramidal movementdisorders and other types of movement disorders (e.g. idiopathicParkinson's disease, secondary Parkinson's disease, Huntingdon'sdisease, dystonia, chorea, tics, myoclonus and athetosis).

In particular, the present invention provides a means for theidentification of NK-1 receptor antagonists which would be effective inan oral medicament for the treatment of movement disorders with orwithout combination with conventional agents currently in use. Theaforementioned patent specifications which describe NK-1 receptorantagonists provide no reliable method for the identification of suchcompounds.

The exceptional pharmacology of the class of NK-1 receptor antagonistsof use in the present invention enables the treatment of movementdisorders, without the need for concomitant therapy.

Furthermore, the exceptional pharmacology of the class of NK-1 receptorantagonists of use in the present invention results in a rapid onset ofaction.

The present invention accordingly provides the use of an orally active,long acting, CNS-penetrant NK-1 receptor antagonist (as hereinafterdefined) for the manufacture of a medicament adapted for oraladministration for the treatment or prevention of movement disorders.

The present invention also provides a method for the treatment orprevention of movement disorders, which method comprises the oraladministration to a patient in need of such treatment of an effectiveamount of an orally active, long acting, CNS-penetrant NK-1 receptorantagonist (as hereinafter defined).

In a further aspect of the present invention, there is provided an oralpharmaceutical composition for the treatment of movement disorders whichcomprises an orally active, long acting, CNS-penetrant NK-1 receptorantagonist (as hereinafter defined), together with a pharmaceuticallyacceptable carrier or excipient.

There exists a patient population in whom dyskinesias are inadequatelytreated with existing neuroleptic therapy. Furthermore, some patientsmay be adversely affected by the side-effects of neuroleptic drugs.

The present invention accordingly provides the use of an orally active,long acting, CNS-penetrant NK-1 receptor antagonist for the manufactureof a medicament adapted for oral administration for the treatment orprevention of dyskinesias in a patient who is non-responsive toneuroleptic agents, or for whom neuroleptic agents are contraindicated.

The present invention also provides a method for the treatment orprevention of dyskinesias in a patient who is non-responsive toneuroleptic agents, or for whom neuroleptic agents are contraindicated,which method comprises oral administration to the patient in need ofsuch treatment of an effective amount of an orally active, long acting,CNS-penetrant NK-1 receptor antagonist.

Whilst it is envisaged that an orally active, long acting, CNS-penetrantNK-1 receptor antagonist will be useful alone in the treatment ofmovement disorders, it will be appreciated that a combination of aconventional antiparkinsonian drug with a NK-1 receptor antagonist mayprovide an enhanced effect in the treatment of akinetic-rigid disorderssuch as parkinsonism. Such a combination may enable a lower dose of theantiparkinsonian agent to be used without compromising the efficacy ofthe antiparkinsonian agent, thereby minimising the risk of adverseside-effects.

Thus, according to a further aspect of the present invention there isprovided the use of a NK-1 receptor antagonist and an antiparkinsonianagent for the manufacture of a medicament for the treatment orprevention of akinetic-rigid disorders.

The present invention also provides a method for the treatment orprevention of akinetic-rigid disorders, which method comprisesadministration to a patient in need of such treatment of an amount of aNK-1 receptor antagonist and an amount of an antiparkinsonian agent,such that together they give effective relief.

In a further aspect of the present invention, there is provided apharmaceutical composition comprising a NK-1 receptor antagonist and anantiparkinsonian agent, together with at least one pharmaceuticallyacceptable carrier or excipient.

It will be appreciated that the NK-1 receptor antagonist and theantiparkinsonian agent may be present as a combined preparation forsimultaneous, separate or sequential use for the treatment or preventionof akinetic-rigid disorders. Such combined preparations may be, forexample, in the form of a twin pack.

In a further or alternative aspect of the present invention, there istherefore provided a product comprising a NK-1 receptor antagonist andan antiparkinsonian agent as a combined preparation for simultaneous,separate or sequential use in the treatment or prevention ofakinetic-rigid disorders.

It will be further appreciated that a combination of a conventionalneuroleptic drug with a NK-1 receptor antagonist may provide an enhancedeffect in the treatment of dyskinesias. Such a combination may enable alower dose of the neuroleptic agent to be used without compromising theefficacy of the neuroleptic agent, thereby minimising the risk ofadverse side-effects. A yet further advantage of such a combination isthat, due to the action of the NK-1 receptor antagonist, adverseside-effects caused by the neuroleptic agent such as acute dystonias,dyskinesias, akathesia and tremor may be reduced or prevented.

Thus, according to a further aspect of the present invention there isprovided the use of a NK-1 receptor antagonist and a neuroleptic agentfor the manufacture of a medicament for the treatment or prevention ofdyskinesias.

The present invention also provides a method for the treatment orprevention of dyskinesias, which method comprises administration to apatient in need of such treatment of an amount of a NK-1 receptorantagonist and an amount of a neuroleptic agent, such that together theygive effective relief.

In a further aspect of the present invention, there is provided apharmaceutical composition comprising a NK-1 receptor antagonist and aneuroleptic agent, together with at least one pharmaceuticallyacceptable carrier or excipient.

It will be appreciated that the NK-1 receptor antagonist and theneuroleptic agent may be present as a combined preparation forsimultaneous, separate or sequential use for the treatment or preventionof dyskinesias. Such combined preparations may be, for example, in theform of a twin pack.

In a further or alternative aspect of the present invention, there istherefore provided a product comprising a NK-1 receptor antagonist andan neuroleptic agent as a combined preparation for simultaneous,separate or sequential use in the treatment or prevention ofdyskinesias.

It will be appreciated that when using a combination of the presentinvention, the NK-1 receptor antagonist and the antiparkinsonian orneuroleptic agent may be in the same pharmaceutically acceptable carrierand therefore administered simultaneously. They may be in separatepharmaceutical carriers such as conventional oral dosage forms which aretaken simultaneously. The term "combination" also refers to the casewhere the compounds are provided in separate dosage forms and areadministered sequentially. Therefore, by way of example, theantiparkinsonian or neuroleptic agent may be administered as a tabletand then, within a reasonable period of time, the NK-1 receptorantagonist may be administered either as an oral dosage form such as atablet or a fast-dissolving oral dosage form. By a "fast-dissolving oralformulation" is meant, an oral delivery form which when placed on thetongue of a patient, dissolves within about 10 seconds.

As used herein, the term "movement disorders" includes akinesias andakinetic-rigid syndromes, dyskinesias and medication-inducedparkinsonism (such as neuroleptic-induced parkinsonism, neurolepticmalignant syndrome, neuroleptic-induced acute dystonia,neuroleptic-induced acute akathisia, neuroleptic-induced tardivedyskinesia and medication-induced postural tremor). Examples of"akinetic-rigid syndromes" include Parkinson's disease, drug-inducedparkinsonism, postencephalitic parkinsonism, progressive supranuclearpalsy, multiple system atrophy, corticobasal degeneration,parkinsonism-ALS dementia complex and basal ganglia calcification.Examples of "dyskinesias" include tremor (including rest tremor,postural tremor and intention tremor), chorea (such as Sydenham'schorea, Huntington's disease, benign hereditary chorea,neuroacanthocytosis, symptomatic chorea, drug-induced chorea andhemiballism), myoclonus (including generalised myoclonus and focalmyoclonus), tics (including simple tics, complex tics and symptomatictics),and dystonia (including generalised dystonia such as iodiopathicdystonia, drug-induced dystonia, symptomatic dystonia and paroxymaldystonia, and focal dystonia such as blepharospasm, oromandibulardystonia, spasmodic dysphonia, spasmodic torticollis, axial dystonia,dystonic writer's cramp and hemiplegic dystonia).

Another "movement disorder" which may be treated according to thepresent invention is Gilles de la Tourette's syndrome, and the symptomsthereof.

As used herein, the term "treatment" refers both to the treatment and tothe prevention or prophylactic therapy of the aforementioned conditions.

Preferred NK-1 receptor antagonists for use in the present invention areselected from the classes of compounds described in European PatentSpecification No. 0 577 394, and International Patent Specification Nos.95/08549, 95/18124, 95/23798, 96/05181, and 98/49710 Application No.PCT/GB97/01630). The preparation of such compounds is fully described inthe aforementioned publications.

Particularly preferred NK-1 receptor antagonists of use in the presentinvention include:

(3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4.5]decane;

(3R,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spirol[4.5]decane;

(±)-(2R,3R,2S,3S)-N-{[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]methyl}-2-phenylpiperidin-3-amine;

2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;

2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(4-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(1-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(2-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxyphosphoryl-1H-1,2,4-triazolo)methyl)morpholine;

2-(S)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(1-monophosphoryl-5-oxo-4H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-N,N-dimethylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;

or a pharmaceutically acceptable salt thereof.

A further preferred NK-1 receptor antagonist of use in the presentinvention is the compound2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine,or a pharmaceutically acceptable salt thereof.

Full descriptions of the preparation of the NK-1 receptor antagonistswhich may be employed in the present invention may be found in thereferences cited herein.

Suitable antiparkinsonian agents of use in combination with a NK-1receptor antagonist include levodopa (with or without a selectiveextracerebral decarboxylase inhibitor such as carbidopa or benserazide),anticholinergics such as biperiden (optionally as its hydrochloride orlactate salt) and trihexyphenidyl (benzhexol) hydrochloride, anddopamine agonists such as alentemol, bromocriptine, fenoldopam,lisuride, naxagolide, pergolide and pramipexole. It will be appreciatedthat the dopamine agonist may be in the form of a pharmaceuticallyacceptable salt, for example, alentemol hydrobromide, bromocriptinemesylate, fenoldopam mesylate, naxagolide hydrochloride and pergolidemesylate. Lisuride and pramipexol are commonly used in a non-salt form.

Suitable neuroleptic agents of use in combination with a NK-1 receptorantagonist include the phenothiazine, thioxanthene, heterocyclicdibenzazepine, butyrophenone, diphenylbutylpiperidine and indoloneclasses of neuroleptic agent. Suitable examples of phenothiazinesinclude chlorpromazine, mesoridazine, thioridazine, acetophenazine,fluphenazine, perphenazine and trifluoperazine. Suitable examples ofthioxanthenes include chlorprothixene and thiothixene. An example of adibenzazepine is clozapine. An example of a butyrophenone ishaloperidol. An example of a diphenylbutylpiperidine is pimozide. Anexample of an indolone is molindolone. Other neuroleptic agents includeloxapine, sulpiride and risperidone. It will be appreciated that theneuroleptic agents when used in combination with a NK-1 receptorantagonist may be in the form of a pharmaceutically acceptable salt, forexample, chlorpromazine hydrochloride, mesoridazine besylate,thioridazine hydrochloride, acetophenazine maleate, fluphenazinehydrochloride, flurphenazine enathate, fluphenazine decanoate,trifluoperazine hydrochloride, thiothixene hydrochloride, haloperidoldecanoate, loxapine succinate and molindone hydrochloride. Perphenazine,chlorprothixene, clozapine, haloperidol, pimozide and risperidone arecommonly used in a non-salt form.

Suitable pharmaceutically acceptable salts of the NK-1 receptorantagonists of use in the present invention include acid addition saltswhich may, for example, be formed by mixing a solution of the compoundwith a solution of a pharmaceutically acceptable non-toxic acid such ashydrochloric acid, fumaric acid, maleic acid, succinic acid, aceticacid, citric acid, tartaric acid, carbonic acid, phosphoric acid orsulphuric acid. Salts of amine groups may also comprise the quaternaryammonium salts in which the amino nitrogen atom carries an alkyl,alkenyl, alkynyl or aralkyl group. Where the compound carries an acidicgroup, for example a carboxylic acid group, the present invention alsocontemplates salts thereof, preferably non-toxic pharmaceuticallyacceptable salts thereof, such as the sodium, potassium and calciumsalts thereof.

Suitable pharmaceutically acceptable salts of the antiparkinsonian andneuroleptic agents used in combination with a NK-1 receptor antagonistaccording to the present invention include those salts described abovein relation to the salts of NK-1 receptor antagonists.

Preferably the compositions containing an NK-1 receptor antagonist ofuse according to the present invention are in unit dosage forms such astablets, pills, capsules, wafers and the like. Additionally, the NK-1receptor antagonists of use according to the present invention may bepresented as granules or powders for extemporaneous formulation asvolume defined solutions or suspensions. Alternatively, the NK-1receptor antagonists of use according to the present invention may bepresented in ready-prepared volume defined solutions or suspensions.Preferred forms are tablets and capsules.

For preparing solid compositions such as tablets, the principal activeingredient is mixed with a pharmaceutical carrier, e.g. conventionaltableting ingredients such as corn starch, lactose, sucrose, sorbitol,talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, andother pharmaceutical diluents, e.g. water, to form a solidpreformulation composition containing a homogeneous mixture of acompound of the present invention, or a non-toxic pharmaceuticallyacceptable salt thereof. When referring to these preformulationcompositions as homogeneous, it is meant that the active ingredient isdispersed evenly throughout the composition so that the composition maybe readily subdivided into equally effective unit dosage forms such astablets, pills and capsules. This solid preformulation composition isthen subdivided into unit dosage forms of the type described abovecontaining from 0.1 to about 500 mg of the active ingredient of thepresent invention. The tablets or pills of the novel composition can becoated or otherwise compounded to provide a dosage form affording theadvantage of prolonged action. For example, the tablet or pill cancomprise an inner dosage and an outer dosage component, the latter beingin the form of an envelope over the former. The two components can beseparated by an enteric layer which serves to resist disintegration inthe stomach and permits the inner component to pass intact into theduodenum or to be delayed in release. A variety of materials can be usedfor such enteric layers or coatings, such materials including a numberof polymeric acids and mixtures of polymeric acids with such materialsas shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the presentinvention may be incorporated for administration orally include aqueoussolutions, suitably flavoured syrups, aqueous or oil suspensions, andflavoured emulsions with edible oils such as cottonseed oil, sesame oil,coconut oil, peanut oil or soybean oil, as well as elixirs and similarpharmaceutical vehicles. Suitable dispersing or suspending agents foraqueous suspensions include synthetic and natural gums such astragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose,methylcellulose, polyvinyl-pyrrolidone or gelatin.

Compositions of the present invention may also be administered via thebuccal cavity using conventional technology, for example, absorptionwafers.

Compositions in the form of tablets, pills, capsules or wafers for oraladministration are particularly preferred.

The present invention further provides a process for the preparation ofa pharmaceutical composition comprising a NK-1 receptor antagonist andan antipsychotic agent, which process comprises bringing a NK-1 receptorantagonist and an antipsychotic agent, into association with apharmaceutically acceptable carrier or excipient.

When administered in combination, either as a single or as separatepharmaceutical composition(s), the NK-1 receptor antagonist and anantipsychotic agent are presented in a ratio which is consistent withthe manifestation of the desired effect. In particular, the ratio byweight of the NK-1 receptor antagonist and the antipsychotic agent willsuitably be between 0.001 to 1 and 1000 to 1, and especially between0.01 to 1 and 100 to 1.

A minimum dosage level for the NK-1 receptor antagonist is about 1 mgper day, preferably about 5 mg per day and especially about 10 mg perday. A maximum dosage level for the NK-1 receptor antagonist is about1500 mg per day, preferably about 1000 mg per day and especially about500 mg per day. The compounds are administered one to three times daily,preferably once or twice a day, and especially once a day.

A minimum dosage level for the antiparkinsonian agent will varydepending upon the choice of agent, but is typically about 0.05 mg perday for the most potent compounds or about 20 mg per day for less potentcompounds. A maximum dosage level for the antipsychotic agent istypically 30 mg per day for the most potent compounds or 500 mg per dayfor less potent compounds. The compounds are administered one to threetimes daily, preferably once or twice a day, and especially once a day.

A minimum dosage level for the neuroleptic agent will vary dependingupon the choice of agent, but is typically about 0.5 mg per day for themost potent compounds or about 20 mg per day for less potent compounds.A maximum dosage level for the neuroleptic agent is typically 30 mg perday for the most potent compounds or 200 mg per day for less potentcompounds. The compounds are administered one to three times daily,preferably once or twice a day, and especially once a day.

It will be appreciated that the amount of the NK-1 receptor antagonistrequired for use in the treatment or prevention of movement diosrderswill vary not only with the particular compounds or compositionsselected but also with the route of administration, the nature of thecondition being treated, and the age and condition of the patient, andwill ultimately be at the discretion of the patient's physician orpharmacist.

When used in combination, it will be appreciated that the amount of theNK-1 receptor antagonist and the antiparkinsonian or neuroleptic agentrequired for use in the treatment or prevention of movement disorderswill vary not only with the particular compounds or compositionsselected but also with the route of administration, the nature of thecondition being treated, and the age and condition of the patient, andwill ultimately be at the discretion of the patient's physician orpharmacist.

Two compounds of use in the present invention which are described inInternational Patent Application No. PCT/GB97/01630 may be preparedaccording to the following methods:

PREPARATION 1 (2S)-1-tert-Butoxycarbonyl-2-phenylpiperidin-3-one

Dimethyl sulfoxide (20.80 ml, 22.90 g, 29.3 mmol) in dichloromethane (75ml) was added dropwise to a cooled (-70° C.) solution of oxalyl chloride(13.95 ml, 20.30 g, 160 mmol) in dichloromethane (350 ml). The mixturewas stirred at -70° C. for 15 minutes, then(2S,3S)-1-tert-butoxycarbonyl-3-hydroxy-2-phenylpiperidine (prepared bythe method described in European Patent Specification number 0 528495-A; 36.91 g, 133 mmol) in dichloromethane (150 ml) was addeddropwise. The mixture was stirred at -70° C. for 20 minutes, thenallowed to warm to -30° C. The mixture was cooled to -50° C. andtriethylamine (55.95 ml, 40.45 g, 400 mmol) was added slowly. Themixture was allowed to warm to 0° C. and diluted with ice-cooleddichloromethane (250 ml). The mixture was washed with ice cold aqueouscitric acid solution (5%, 2×300 ml) and water (300 ml), dried (MgSO₄),and the solvent was evaporated under reduced pressure to give the titlecompound as a yellow oil (42.3 g), which was used immediately withoutfurther purification. ¹ H NMR (250 MHz, CDCl₃) δ7.5-7.3 (5H, m), 5.8(1H, br s), 4.2 (1H, br s), 3.4 (1H, m), 2.6 (2H, m), 2.0 (2H, m), and1.54 (9H, s).

PREPARATION 2(2S,3R)-1-tert-Butoxycarbonyl-3-hydroxy-3-(2-methylene-3-phenoxypropyl)-2-phenylpiperidine

A solution of 3-(chloromagnesio)-2-(phenoxymethyl)-1-propene in THF(0.91M, 3 ml) (Louw et. al., Tetrahedron, 48, 6087-6104, 1992, preparedfrom 2.74 mmol of 3-chloro-2-(phenoxymethyl)-1-propene) was slowly addedto a solution of (2S)-1-tert-butoxycarbonyl-2-phenylpiperidin-3-one(Preparation 1) in THF (3 ml). The mixture was stirred at roomtemperature for 1 hours, then saturated aqueous ammonium chloride (20ml) was added and the mixture was extracted with ethyl acetate (20 ml).The organic phase was washed with brine, dried (MgSO₄) and the solventwas evaporated under reduced pressure. The residue was purified bycolumn chromatography on silica gel, eluting with hexane/ethyl acetate(100:0 increasing to 80:20) to give the title compound. ¹ H NMR (360MHz, CDCl₃) δ7.48 (2H, d, J=6.9 Hz), 7.35-7.2 (6H, m), 6.9-6.88 (3H, m),5.4 (1H, s), 5.15 (2H, d, J=13.7 Hz), 4.61 (2H, s), 4.11 (2H, m), 3.17(1H, m), 2.66 and 2.59 (2H, AB d, J=14.0 Hz), 1.95 (2H, m), 1.79 (2H,m), and 1.36 (9H, s). m/z (ES⁺) 424 (M+1).

PREPARATION 3(5R,6S)-3-Methylene-6phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

To a cooled (-80° C.) solution of(2S,3R)-1-tert-butoxycarbonyl-3-hydroxy-3-(2-methylene-3-phenoxypropyl)-2-phenylpiperidine(Preparation 2, 1.53 g, 3.62 mmol) in THF (20 ml) was added n-butyllithium (2.5M in hexanes, 1.45 ml, 3.62 mmol) followed by a solution ofzinc chloride (0.5M in THF, 7.24 ml, 3.62 mmol). The solution wasallowed to warm to room temperature andtetrakis(triphenylphosphine)palladium (0) (0.23 g, 0.2 mmol) was added.The mixture was degassed with bubbling nitrogen and heated under refluxfor 16 hours. The mixture was cooled and the solvent was evaporatedunder reduced pressure. The residue was partitioned between ethylacetate and 2M sodium hydroxide. The organic phase was washed withsaturated brine, dried (MgSO₄) and purified by chromatography on acolumn containing silica gel (eluting with hexane containing increasingproportions of ethyl acetate between 0% to 5%). Evaporation of thefractions gave(6S,5R)-3-methylene-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane.¹ H NMR (360 MHz, CDCl₃) δ7.58 (2H, d, J=8.4 Hz), 7.32-7.21 (3H, m),5.23 (1H, s), 5.06 (1H, m), 4.97 (1H, m), 4.39 (2H, AB d, J=13.3 Hz),3.99 (1H, dd, J=13.3, 4.48 Hz), 2.83 (1H, ABd J=15.5 Hz), 2.7 (1H, tdJ=12.5, 3.93 Hz), 2.5 (1H, ABd, J=15.4 Hz), 2.15 (2H, td, J=12., 0.4Hz), 1.69 (2H, m), and 1.46 (9H,s). m/z (ES⁺) 329 (M+2H-^(t) BuOCO).

PREPARATION 4(5R,6S)-3-Keto-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

Through a cooled (-80° C.) solution of(5R,6S)-3-methylene-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane(Preparation 3; 0.665 g) in dichloromethane (5 ml) and methanol (5 ml)was bubbled a mixture of ozone and oxygen for 45 minutes. After thesolution had been purged with nitrogen, dimethyl sulphide (0.5 ml) wasadded and then stirred under nitrogen at room temperature for 16 hours.The solvent was removed in vacuo and the residue partitioned betweenethyl acetate and water. The organic phase was dried (MgSO₄), evaporatedand the residue purified by chromatography on a column containing silicagel (eluting with hexane containing increasing proportions of ethylacetate between 0% to 10%). Evaporation of the fractions gave the titlecompound. ¹ H NMR (250 MHz, CDCl₃) δ7.58 (2H, d, J=6.2 Hz), 7.37-7.26(3H, m), 5.3 (1H, s), 4.15 and 4.09 (2H, AB d, J=17.4 Hz), 3.97 (1H, m),2.80 (1H, td, J=12.9, 4.0 Hz), 2.74 and 2.48 (2H, ABd, J=18.1 Hz), 2.29(2H, m), 1.88-1.63 (2H, m), and 1.44 (9H, s). m/z (ES⁺) 332 (M+1).

PREPARATION 5(5R,6S)-3-Trifluoromethylsulfonyloxy-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene

To a cooled (-80° C.) solution of 1M sodium hexamethyldisilazide (0.38ml, 0.38 mmol) in THF was added a solution of(5R,6S)-3-keto-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane(Preparation 4; 0.105 mg, 0.319 mmol) in THF (3 ml). The solution wasstirred for 1 hours at -80° C. then a solution of2-[N,N-bis(trifluoromethylsulfonyl)amino]-5-chloropyridine (0.163 g,0.415 mmol) in THF (3 ml) was added. The solution was stirred at -80° C.for 30 minutes then at room temperature for 30 minutes before beingquenched by addition of saturated ammonium chloride solution and ethylacetate. The dried (MgSO₄) organic phase was purified by chromatographyon a column containing silica gel (eluting with hexane containingincreasing proportions of ethyl acetate between 0% to 5%). Evaporationof the fractions gave the title compound. ¹ H NMR (360 MHz, CDCl₃) δ7.4(2H, d, J=7.3 Hz), 7.3-7.22 (3H, m), 6.01 (1H, t, J=2.13 Hz), 5.13 (1H,s), 4.56 and 4.26 (2H, ABdd, J=12.4, 1.97 Hz),4.10 (1H, dt, J=12.6, 4.22Hz), 3.00 (1H, m), 2.28-2.04 (2H, m), 1.88-1.76 (2H, m), and 1.37 (9H,s). m/z (ES⁺) 464 (M+1).

PREPARATION 6(5R,6S)-3-Trimethylstannyl-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene

To a degassed solution of(5R,6S)-3-trifluoromethylsulfonyloxy-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene(Preparation 5; 0.482 g, 1.04 mmol), lithium chloride (0.264 g, 6.25mmol), lithium carbonate (0.076 g) and hexamethyl distannane(0.96 g, 2.9mmol) in THF (10 ml) was added triphenylphosphine palladium (0) (0.06g). The solution was degassed and then heated at 60° C. for 5 hoursunder nitrogen. Water (20 ml) and ethyl acetate (20 ml) were added andthe dried organic phase was purified by chromatography on a columncontaining silica gel (eluting with hexane containing increasingproportions of ethyl acetate between 0% to 5%). Evaporation of thefractions gave the title compound as a crystalline solid. ¹ H NMR (360MHz, CDCl₃) δ7.25 (2H, d, J=7.3 Hz), 7.1-7.0 (3H, m), 5.83 (1H, t, J=2.5Hz), 4.78 (1H, s), 4.48 and 4.02 (2H, dd, J=12.9, 2.3 Hz), 3.96 (1H, dd,J=6.16, 13.4 Hz), 2.95 (1H, td, J=13.3, 4.5 Hz), 1.84 (1H, m), 1.68 (1H,m), 1.60 (2H, m), 1.19 (9H, s), and 0.0 (6H, s).

PREPARATION 7(2S,3R)-1-tert-Butoxycarbonyl-3-hydroxypropyn-1-yl)-2-phenylpiperdin-3-ol

O-Trimethylsilylpropargyl alcohol (24.51 ml, 20.47 g, 160 ml) was addedslowly to a cooled (-10° C.) solution of ethylmagnesium bromide (1M intetrahydrofuran, 160 ml, 160 mmol). The mixture was stirred at 0° C. for20 minutes, then at room temperature for 2 hours. The mixture was cooledto -10° C. and a solution of(2S)-1-tert-butoxycarbonyl-2-phenylpiperidin-3-one (Preparation 1; 42.3g) in tetrahydrofuran (200 ml) was added dropwise over 30 minutes.(Internal temperature below -5° C.). The mixture was stirred at roomtemperature for 14 hours, poured into water (300 ml) and saturatedaqueous ammonium chloride (300 ml) and extracted with ethyl acetate(2×300 ml). The combined organic fractions were washed with brine (300ml), dried (MgSO₄) and the solvent was evaporated under reducedpressure. The residue was dissolved in ethyl acetate (500 ml) and asolution of tetrabutylammonium fluoride (1M in THF, 160 ml, 160 mmol)was added dropwise. The mixture was stirred at room temperature for 30minutes, water (300 ml) was added, and the layers were separated. Theaqueous layer was extracted with ethyl acetate (2×300 ml) and thecombined organic fractions were washed with water (300 ml) and brine(300 ml), dried (MgSO₄) and the solvent was evaporated under reducedpressure to give the crude title compound as an orange oil (45 g). Thecrude material was purified by flash column chromatography on silicagel, eluting with hexane/ethyl acetate (90:10 increasing to 25:75) togive the title compound as an amber oil (32.2 g). ¹ H NMR (CDCl₃)δ7.53-7.55 (2H, m), 7.19-7.35 (3H, m), 5.56 (1H, s), 4.27 (2H, s),3.99-4.03 (1H, m), 3.25 (1H, br s), 2.77-2.81 (1H, m), 2.77 (1H, br s),2.12-2.20 (1H, m), 1.91-1.99 (2H, m), 1.77-1.83 (1H, m), and 1.39(9H,s).

PREPARATION 8 2-Bromo-4-(trifluoromethoxy)phenol

To a cooled (0° C.) solution of 4-trifluoromethoxyphenol (35.6 g, 0.2mol) in chloroform (280 ml) was added dropwise a solution of bromine (32g, 0.2 mol) in chloroform (50 ml). The solution was stirred at 0° C. for1 hour and at room temperature for 2 hours. Dichloromethane (200 ml) andwater (400 ml) ware added and the organic phase was washed further withwater(400 ml), brine (200 ml) and dried (MgSO₄). The solvent was removedand the residue was purified by distillation at reduced pressure to givethe title compound. ¹ H NMR (250 MHz, CDCl₃) δ7.38 (1H, d, J=2.1 Hz),7.13 (1H, dd, J=9.1, 2.1 Hz), 7.03 (1H, d, J=9.1 Hz), and 5.53 (1H, s).

PREPARATION 9 2-Benzyloxy-5-(trifluoromethoxy)bromobenzene

2-Bromo-4-(trifluoromethoxy)phenol (Preparation 8; 5 g, 20 mmol) wasdissolved in N,N-dimethylformamide (60 ml), and potassium carbonate (5.4g, 40 mmol) was added, followed by benzyl bromide (3.5 ml, 30 mmol), andthe reaction was stirred at ambient temperature for 15 hours. Thereaction was diluted with water (150 ml) and extracted into ethylacetate (3×60 ml). The combined organic fractions were washed with water(100 ml), brine (100 ml), dried (MgSO₄) and evaporated in vacuo.Purification on silica, eluting with 2% and 5% ethyl acetate in hexanegave the title compound as a clear oil (6.7 g, 96%). ¹ H NMR (250 MHz,CDCl₃) δ5.47 (2H, s), 7.23 (1H, d, J=9 Hz), 7.43 (1H, dd J=8.2, 2.9 Hz),and 7.75 (6H, m).

PREPARATION 10Z-(2S,3R)-1-tert-Butoxycarbonyl-3-3-hydroxyprop-1-en-1-yl)-2-phenylpiperdin-3-ol

Palladium on calcium carbonate, poisoned with lead (Lindlar catalyst, 2g) was added to a solution of(2S,3R)-1-tert-butoxycarbonyl-3-(3-hydroxypropyn-1yl)-2-phenylpiperidin-3-ol(Preparation 7; 32 g, 96.6 mmol) in ethyl acetate (300 ml) and themixture was stirred under hydrogen (1 atmosphere) for 4 hours. Themixture was filtered and the solvent was evaporated under reducedpressure to give the title compound as an oil (32 g, 100%). ¹ H NMR (360MHz, CDCl₃) δ7.42 (2H, d, J=7.6 Hz), 7.35-7.25 (3H, m), 5.83 (1H, d,J12.3 Hz), 5.68 (1H, dt, J=12.3, 6.0 Hz), 5.06 (1H, s), 4.27 (1H, m),4.12 (2H, m), 3.32 (1H, m), 3.13 (1H, s), 2.28 (1H, t, J=5.9 Hz), 2.02(1H, m), 1.92-1.78 (3H, m), and 1.32 (9H, s). m/z (ES⁺) 334 (M+1).

PREPARATION 11(5R,6S)-6-Phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene

Diethylazodicarboxylate (18.2 ml, 115 mmol) in THF (100 ml) was addeddropwise to a solution ofZ-(2S,3R)-1-tert-butoxycarbonyl-3-(3-hydroxyprop-1-en-1-yl)-2-phenylpiperidin-3-ol(Preparation 10; 32 g, 96 mmol) and triphenylphosphine (30.2 g, 115mmol) in THF (700 ml). The mixture was stirred at 0° C. for 30 minutesthen at room temperature for 1.5 hours. The solvent was evaporated underreduced pressure and the residue was purified by flash columnchromatography on silica gel, eluting with hexane/ethyl acetate (95:5increasing to 80:20) to give the title compound as a colorless solid(23.4 g, 77%). ¹ H NMR (CDCl₃) δ7.45 (2H, d, J=7.4 Hz), 7.27 (2H, t,J=7.4 Hz), 7.20 (1H, t, J=7.4 Hz), 6.03 (1H, dt, J=6.1, 2.0 Hz), 5.68(1H, dt, J=6.1, 2.0 Hz), 5.06 (1H, s), 4.61 (1H, dt, J=13.1, 2.0 Hz),4.32 (1H, dt, J=13.1, 2.0 Hz), 4.08 (1H, m), 3.05 (1H, m), 2.05 (1H, m),1.75 (3H, m), and 1.37 (9H, s). m/z (ES⁺) 316 (M+1).

PREPARATION 12 2-Benzyloxy-5-(trifluoromethoxy)benzene

Benzyl bromide (66.17 ml, 95.35 g, 0.56 mol) was added to a mixture of4-(trifluoromethoxy)phenol (90.26 g, 0.51 mol) and potassium carbonate(140.97 g, 1.2 mol) in dimethylformamide (160 ml) and the mixture wasstirred at room temperature for 72 hours. The mixture was poured intowater (1.5 l) and extracted with ethyl acetate (3×500 ml). The combinedorganic fractions were washed with aqueous sodium carbonate (saturated,500 ml), dried (MgSO₄) and the solvent was evaporated under reducedpressure to give the title compound as a colorless solid (133.5 g, 99%).¹ H NMR (360 MHz, CDCl₃) δ7.39 (5H, m), 7.14 (2H, d, J=9.0 Hz), 6.95(2H, d, J=9.0 Hz), and 5.05 (2H, s).

PREPARATION 13 2-Benzyloxy-5-(trifluoromethoxy)iodobenzene

Iodine (71.96 g, 0.28 mol) in chloroform was added dropwise to a mixtureof 2-benzyloxy-5-(trifluoromethoxy)benzene (Preparation 12, 73.06 g,0.27 mol) and silver trifluoroacetate (71.57 g, 0.32 mol) indichloromethane and the mixture was stirred at room temperature for 18hours. The mixture was filtered through celite, washed with aqueoussodium thiosulfate (5%, 2×2 l), dried (MgSO₄) and the solvent wasevaporated under reduced pressure. The residue was purified by flashcolumn chromatography on silica gel, eluting with hexane/ethyl acetate,to give the title compound as a colorless oil (108.03 g), containing 11%unreacted 2-benzyloxy-5-(trifluoromethoxy)iodobenzene. ¹ H NMR (360 MHz,CDCl₃) δ7.67 (1H, d, J=2.8 Hz), 7.40 (5H, m), 7.16 (1H, dd, J=8.9, 2.8Hz), 6.82 (1H, d, J=8.9 Hz), and 5.14 (2H, s).

PREPARATION 14(5R,6S)-3-(2-Benzyloxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene

(5R,6S)-3-Trimethylstannyl-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene(Preparation 6; 6.43 mmol), lithium chloride (0.163 g),benzyloxy-5-(trifluoromethoxy)phenol (Preparation 9; 7.7 mmol) intoluene (25 ml) was degassed before addition of triphenylphosphinepalladium (0) (0.37 g). The solution was degassed thoroughly beforeheating to 110° C. for 14 hours. The solution was partitioned betweenwater and ethyl acetate and the dried organic phase was purified bychromatography on a column containing silica gel (eluting with hexanecontaining increasing proportions of ethyl acetate between 0% to 4%) togive the title compound. ¹ H NMR (360 MHz, CDCl₃) δ1.33 (9H, s), 1.65(1H, m), 1.76 (2H, m), 2.08 (1H, m), 3.11 (1H, m), 4.08 (1H, m), 4.60(1H, dd, J=12.2 Hz, J=2 Hz), 4.92 (1H, dd, J=12.1 Hz, J=1.8 Hz), 5.08(1H, s), 5.1 (2H, q, J=11.5 Hz), 6.65 (1H, s), 6.94 (2H, d, J=8.9 Hz),7.08 (1H, d, J=9 Hz), 7.18 (2H, t, J=8.1 Hz), 7.25 (3H, m), 7.38 (5H,m).

PREPARATION 15(3S,5R,6S)-3-(2-Hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

(5R,6S)-3-(2-Benzyloxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene(Preparation 14) (3.88 g) was dissolved in ethyl acetate (15 ml) andmethanol (15 ml). Palladium hydroxide on carbon (1.00 g) was added andthe suspension was shaken under a hydrogen atmosphere (50 psi) for 72hours. The mixture was filtered and the solvent was evaporated underreduced pressure. The residue was purified by medium pressurechromatography on silica gel, eluting with hexane/ethyl acetate (75:25)to give(3R,5R,6S)-3-(2-hydroxy-5-(trifluoromethoxy)phenyl)-6-phlenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spirol[4.5]decane(191 mg), ¹ H NMR (250 MHz, CDCl₃) δ7.70 (2H, d, J=7.3 Hz), 7.33 (2H, t,J=7.3 Hz), 7.26 (1H, d, J=7.3 Hz), 7.05 (1H, br s), 6.96 (2H, m), 6.82(1H, d, J=9.4 Hz), 5.43 (1H, s), 4.27 (1H, m), 4.01 (1H, m), 3.95 (1H,m), 3.73 (1H, m), 2.73 (2H, m), 2.33 (1H, m), 1.87-1.58 (4H, m); and1.50 (9H, s) and(3S,5R,6S)-3-(2-hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane(2.3 g), ¹ H NMR (360 MHz, CDCl₃) δ1.38 (9H, s), 1.73 (2H, m), 1.81 (1H,m), 2.18 (2H, m), 2.50 (1H, m), 2.81 (1H, m), 3.62 (1H, t, J=7.2 Hz),3.92 (1H, m), 3.98 (1H, d, J=13.2 Hz), 4.23 (1H, m), 5.33 (1H, s), 6.75(1H, d, J=8.5 Hz), 6.94 (2H, m), 7.25 (1H, m), 7.31 (2H, m), and 7.55(2H, d, J=7.8 Hz).

PREPARATION 16(3R,5R,6S)-3-(2-Benzyloxy-5-trifluoromethoxy)phenyl)-6-phepyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

A mixture of 2-benzyloxy-5-(trifluoromethoxy)iodobenzene (Preparation13, 21.8 g, 55.2 mmol),(5R,6S)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene(Preparation 11, 7.0 g, 22.1 mmol), tetra-n-butylammonium chloride (6.18g, 22.2 mmol), lithium chloride (9.35 g, 0.22 mol) and potassium formate(5.64 g, 67.0 mmol) in dimethylformamide (100 ml) was degassed with afirestone valve (5×). Palladium acetate (491 mg, 2.2 mmol) was added andthe mixture was degassed with a firestone valve (5×). The mixture wasstirred at 60° C. for 15 hours, then further2-benzyloxy-5-(trifluoromethoxy)iodobenzene (Preparation 13, 4.32 g,11.0 mmol), potassium formate (2.78 g, 33.5 mmol) and palladium acetate(260 mg, 1.1 mmol) were added. The mixture was stirred at 60° C. for 22hours, cooled and filtered. The solvent was evaporated under reducedpressure, water (600 ml) was added and the mixture was extracted withethyl acetate (2×300 ml). The combined organic fractions were washedwith brine (300 ml), dried (MgSO₄) and the solvent was evaporated underreduced pressure. The residue was purified by flash columnchromatography on silica gel, eluting with hexane/dichloromethane (75:25increasing to 0:100) then dichloromethane/ethyl acetate (95:5), to givethe title compound (9.42 g, 73%). ¹ H NMR (360 MHz, CDCl₃) δ7.56 (2H, d,J=7.7 Hz), 7.40-7.20 (8H, m), 7.14 (1H, d, J=2.0 Hz), 7.00 (1H, dd,J=8.9, 2.0 Hz), 6.88 (1H, d, J=8.9 ) Hz), 5.30 (1H, s), 5.08 (2H, s),4.27 (1H, m), 3.97 (1H, m), 3.87 (2H, m), 2.78 (1H, m), 2.56 (1H, m),2.15 (1H, m), 1.96 (1H, m), 1.67 (3H, m), and 1.42 (9H, s).

PREPARATION 17(3R,5R,6S)-3-(2-Hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

Palladium on carbon (10%, 0.59 g) was added to a solution of(3R,5R,6S)-3-(2-benzyloxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane(Preparation 16, 6.10 g, 10.5 mmol) in methanol-water (99:1, 200 ml) andthe mixture was stirred under hydrogen (50 psi.) for 72 hours. Themixture was filtered, washing with ethanol, and the solvent wasevaporated under reduced pressure. The residue was purified by flashcolumn chromatography on silica gel, eluting with dichloromethane/ethylacetate (99:1 increasing to 90:10) to give the title compound. ¹ H NMR(360 MHz, CDCl₃) δ7.70 (2H, d, J=7.3 Hz), 7.33 (2H, t, J=7.3 Hz), 7.26(1H, d, J=7.3 Hz), 7.05 (1H, br s), 6.96 (2H, m), 6.82 (1H, d, J=9.4Hz), 5.43 (1H, s), 4.27 (1H, m), 4.01 (1H, m), 3.95 (1H, m), 3.73 (1H,m), 2.73 (2H, m), 2.33 (1H, m), 1.87-1.58 (4H, m), and 1.50 (9H, s).

PREPARATION 18(3S,5R,6S)-3-[2-(1-Phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

(3S,5R,6S)-3-(2-Hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane(Preparation 15) (290 mg, 0.59 mmol) was dissolved in toluene (5 ml) andsilver carbonate (179 mg, 0.65 mmol) was added in one portion.(1-Iodocycloprop-1-yl)phenylsulfide (Cohen T. and Matz J. R., J. Am.Chtem. Soc. 1980, 102, 6902) (180 mg, 0.65 mmol) was then added over oneminute at room temperature. The mixture was stirred at 55° C. for 4hours, then further portions of silver carbonate (179 mg, 0.65 mmol) and(1-iodocycloprop-1-yl)phenylsulfide (180 mg, 0.65 mmol) were added. Themixture was stirred at 55° C. for a further 3 hours, cooled, filteredand the solvent was evaporated under reduced pressure. The residue waspurified by column chromatography on silica gel, eluting withhexane/ethyl acetate (90:10 increasing to 80:20) to give the titlecompound as a colourless oil (120 mg, 32%). ¹ H NMR (250 MHz, CDCl₃)δ7.55-7.44 (4H, m), 7.36-7.23 (7H, m), 7.13-7.02 (2H, m), 5.16 (1H, brs), 4.09 (1H, t, J=6 Hz), 4.03-3.92 (1H, m), 3.67-3.49 (2H, m),2.94-2.79 (1H, m), 2.26 (1H, dd, J=7.9, 12.9 Hz), 2.15-2.01 (2H, m),1.76-1.59 (3H, m), 1.53-1.45 (4H, m), and 1.36 (9H, s). m/z (ES⁺) 642(M+1).

PREPARATION 19(3R,5R,6S)-3-[2-(1-Phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

Prepared from(3R,5R,6S)-3-(2-hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane(Preparation 17) according to the method of Preparation 18. ¹ H NMR (360MHz, CDCl₃) δ7.57 (2H, app. d, J=7.6 Hz), 7.45 (2H, app. d, J=7.7 Hz),7.36-7.19 (7H, m), 7.16-7.06 (2H, m), 5.28 (1H, br s), 4.13 (1H, app. t,J=7.8 Hz), 3.96 (1H, br. d, J=13 Hz), 3.80-3.60 (2H, m), 2.79 (1H, br.t, J=13 Hz), 2.50 (1H, dd, J=13, 7.9 Hz), 2.17 (1H, dt, J=13, 4.6 Hz),1.80 (1H, dd, J=12, 9.8 Hz), 1.75-1.38 (7H, m), and 1.44 (9H, s). m/z(ES⁺) 642 (M+1).

PREPARATION 20(3R,5R,6S)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

Naphthalene (120 mg, 0.936 mmol) was dissolved in THF (1.5 ml) undernitrogen and freshly cut lithium metal (7.0 mg, 0.94 mmol) was added.The mixture was then sonicated at room temperature for 20 minutes toproduce a dark green solution of lithium naphthalenide. This solutionwas cooled to -78° C., then(3S,5R,6S)-3-[2-(1-phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane(Preparation 18) (120 mg, 0.187 mmol) in THF (0.5 ml) was added over 1minute. The reaction mixture was stirred for 30 minutes, then water (5ml) and ether (10 ml) were added. The layers were separated and theaqueous layer was extracted with ether (10 ml). The combined organicfractions were dried (MgSO₄) and the solvent was evaporated underreduced pressure. The residue was purified by column chromatography onsilica gel, eluting with hexane/ethyl acetate (90:10 increasing to80:20) to give the title compound as a colourless oil (58.6 mg, 59%). ¹H NMR (250 MHz, CDCl₃) δ7.58-7.52 (2H, m), 7.36-7.17 (4H, m), 7.10-7.01(2H, m), 5.18 (1H, br s), 4.20 (1H, t, J=6.7 Hz), 4.05-3.95 (1H, m),3.76-3.55 (3H, m), 2.92-2.79 (1H, m), 2.37 (1H, dd, J=12.9, 7.8 Hz),2.18-2.06 (2H, m), 1.80-1.67 (3H, m), 1.38 (9H, s), and 0.86-0.73 (4H,m). m/z (ES⁺) 534 (M+1).

PREPARATION 21(3R,5R,6S)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

Naphthalene (120 mg, 0.936 mmol) was dissolved in THF (1.5 ml) undernitrogen and freshly cut lithium metal (7.0 mg, 0.94 mmol) was added.The mixture was then sonicated at room temperature for 20 minutes toproduce a dark green solution of lithium naphthalenide. A solution of(3R,5R,6S)-3-[2-(1-phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane(Preparation 19, 135 mg, 0.2 mmol) in THF (2 ml) under nitrogen wascooled to -78° C. and the solution of lithium naphthalenide in THF wasadded dropwise until the intense green colour persisted. The reactionwas then stirred for one minute, water (5 ml) was added and the mixturewas warmed to room temperature. Ether (10 ml) was added and the layerswere separated. The aqueous phase was extracted with a further portionof ether (10 ml) and the combined organic phases were dried (MgSO₄) andthe solvent was evaporated under reduced pressure. The residue waspurified by column chromatography on silica gel, eluting withhexane/ethyl acetate (50:50) to give the title compound as a colourlessoil (87 mg, 78%). ¹ H NMR (360 MHz, CDCl₃) δ7.59 (2H, app. d, J=7.6 Hz),7.32 (2H, app. t, J=7.6 Hz), 7.27-7.18 (2H, m), 7.11-7.03 (2H, m), 5.32(1H, br s), 4.29-4.21 (1H, m), 3.97 (1H, br. d, J=13 Hz), 3.83-3.68 (3H,m), 2.76 (1H, dt, J=13, 4.1 Hz), 2.55 (1H, dd, J=13, 7.2 Hz), 2.22 (1H,dt, J=12, 5.2 Hz), 1.85 (1H, dd, J=13, 9.9 Hz), 1.80-1.63 (3H, m), 1.46(9H, s), and 0.82-0.76 (4H, m). m/z (ES⁺) 534 (M+1).

COMPOUND A(3S,5R,6S)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4.5]decaneHydrochloride

Trifluoroacetic acid (2.5 ml) was added dropwise to a stirred, cooled 0°C.) solution of(3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane(Preparation 20; 492 mg, 0.92 mmol) in dichloromethane (25 ml) and themixture was stirred at room temperature for 3 hours. The mixture waspoured into water (50 ml), the pH was adjusted to 10.0 with aqueoussodium hydroxide (4M) and the mixture was extracted with dichloromethane(3×50 ml). The combined organic fractions were dried (MgSO₄) and thesolvent was evaporated under reduced pressure. The residue was purifiedby flash column chromatography on silica gel, eluting withdichloromethane/methanol/ammonia (aq.) (96:4:0.4 increasing to94:6:0.6). The residue was dissolved in ethanol (20 ml), cooled in iceand ethereal hydrogen chloride (1M, 1.8 ml, 1.8 mmol) was addeddropwise. The mixture was stirred at 0° C. for 5 minutes, then thesolvent was evaporated under reduced pressure. The residue wascrystallized from ether (20 ml)/ethanol (0.5 ml) and the solid wascollected and dried in vacuo to give the title compound as a colorlesssolid (354 mg, 89%). m.p. 214-216° C., ¹ H NMR (500 MHz, CD₃ OD) δ7.59(2H, m), 7.52 (3H, m), 7.26 (1H, d, J=8.9 Hz), 7.03 (1H, dd, J=8.9, 2.2Hz), 6.20 (1H, d, J=2.2 Hz), 4.85 (2H, br s), 4.43 (1H, s), 4.19 (1H, t,J=8.0 Hz), 3.87 (1H, quin, J=8.0 Hz), 3.76 (1H, m), 3.44 (1H, m), 3.25(2H, m) 2.29-1.78 (6H, m), 0.80 (2H, m), and 0.66 (2H, m). m/z (ES⁺) 434(M+1). Found: C, 61.41; H, 5.51; N, 3.08. C₂₄ H₂₆ F₃ NO₃.HCl requires:C, 61.34; H, 5.79; N, 2.98%.

COMPOUND B(3R,5R,6S)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4.5]decane

Prepared from the compound of Preparation 21 according to the methodused for Compound A. ¹ H NMR (360 MHz, CDCl₃) δ7.50-7.42 (2H, m),7.36-7.26 (3H, m), 7.03 (1H, d, J=8.9 Hz), 6.95 (1H, br. d, J=8.9 Hz),6.81 (1H, br s), 3.92 (1H, t, J=7.4 Hz), 3.62-3.53 (2H, m), 3.50 (1H,s), 3.20 (1H, dd, J=12, 4.2 Hz), 2.77 (1H, dt, J=12, 2.8 Hz), 2.30-1.93(4H, m), 1.87 (1H, br s), 1.71-1.49 (3H, m), 0.76-0.65 (2H, m), and0.65-0.54 (2H, m). m/z (ES⁺) 434 (M+1).

A further compound and diastereomers thereof of use in the presentinvention may be prepared according to the following method:

DESCRIPTION 12-(1-Phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)benzaldehyde

Silver carbonate (1.2 g, 4.34 mmol) was added to a solution of2-hydroxy-5-(trifluoromethoxy)benzaldehyde (0.5 g, 2.43 mmol) and(1-iodocycloprop-1-yl)phenylsulfide (Cohen T. and Matz J. R., J. Am.Chem. Soc. 1980, 102, 6902) (1.2 g, 4.34 mmol) in toluene (30 mL) andthe mixture was stirred at 40° C. overnight. The mixture was cooled,diluted with ethyl acetate and filtered, washing well with ethylacetate. The mixture was washed with aqueous sodium hydroxide, dried(MgSO₄) and the solvent was evaporated under reduced pressure. Theresidue was purified by flash column chromatography on silica gel,eluting with hexane/Et₂ O (95:5), to give the title compound as a yellowoil (191 mg, 27%). ¹ H NMR (360 MHz, CDCl₃) δ1.51-1.56 (2H, m),1.44-1.48 (2H, m), 7.25-7.35 (7H, m), 7.69 (1H, d, J 2.0 Hz), and 10.26(1H, s).

DESCRIPTION 2 2-Cyclopropoxy-5-(trifluoromethoxy)benzaldehyde

Freshly cut lithium metal (97 mg, 13.9 mmol) was added to a solution ofnaphthalene (1.77 g, 13.9 mmol) in THF (20 mL) and the mixture wassonicated at room temperature for 30 min. to produce a dark greensolution of lithium naphthalenide. A solution of2-(1-phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)benzaldehyde(Description 1, 96 mg, 0.27 mmol) in THF (2 mL) was cooled to -78° C.and the solution of lithium naphthalenide in THF (2 mL) was addeddropwise until the intense green colour persisted. The reaction was thenstirred for 5 min., water (6 mL) was added and the mixture was warmed toroom temperature. The mixture was extracted with ethyl acetate, thecombined organic fractions were dried (MgSO₄) and the solvent wasevaporated under reduced pressure. The residue was purified by flashcolumn chromatography on silica gel, eluting with hexane/Et₂ O (80:20),to give to give the title compound as a colourless oil (4 mg, 6%). ¹ HNMR (360 MHz, CDCl₃) δ0.86 (4H, m), 3.82-3.9 (1H, m), 7.42 (2H, m), 7.62(1H, d, J 2.5 ) Hz), and 10.36 (1H, s).

DESCRIPTION 3 2-Nitro-4-trifluoromethoxy)phenol

Iron(111)nitrate nonahydrate (1.97 g, 4.87 mmol) was added to a solutionof 4-(trifluoromethoxy)phenol (2 g, 11.24 mmol) in ethanol (20 mL) andthe mixture was heated under reflux overnight. The mixture was allowedto cool to room temperature, acidified to pH 1 with aqueous hydrochloricacid (1M) and extracted with ethyl acetate. The combined organicfractions were dried (MgSO₄), and the solvent was evaporated underreduced pressure. The residue was purified by short columnchromatography on silica gel, eluting with hexane/EtOAc (70:30), to givethe title compound as a yellow oil (2.25 g, 89%). ¹ H NMR (360 MHz,CDCl₃) δ10.53 (1H, s), 8.01 (1H, d, J 3.0 Hz), 7.49 (1H, dd, J 9.1, 3.0Hz), and 7.23 (1H, d, J 9.1 Hz).

DESCRIPTION 42-(1-Phenylthiocycloprop)-1-yl)oxy-5-(trifluoromethoxy)nitrobenzene

Prepared from the compound of Description 3 according to the method ofDescription 1. ¹ H NMR (360 MHz, CDCl₃) δ7.73 (1H, d, J 2.7 Hz), 7.58(1H, d, J 9.2 Hz), 7.50-7.24 (6H, m), 1.57-1.53 (2H, m), and 1.44-1.40(2H, m).

DESCRIPTION 5 2-Cyclopropoxy-5-(trifluoromethoxy)benzeneamine

Prepared from the compound of Description 4 according to the method ofDescription 2. ¹ H NMR (360 MHz, CDCl₃) δ7.06 (1H, dd, J 2.8, 6.7 Hz),6.56 (2H, m), 3.83 (2H, br s), 3.74 (1H, m), and 0.79 (4H, m). m/z (ES⁺)234 (M+1).

DESCRIPTION 62-(1-Phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)benzeneamine

Iron powder (13.5 g, 241 mmol) was added to a suspension of2-(1-phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)nitrobenzene(Description 4, 11.27 g, 30.1 mmol) in water (300 mL) and acetic acid(75 mL) and the mixture was stirred at 80° C. overnight. The mixture wascooled and filtered through celite, washing with ether. The filtrate wasextracted with ether, the combined organic fractions were washed withaqueous sodium hydroxide (1M), dried (MgSO₄), and the solvent wasevaporated under reduced pressure. The residue was purified by flashcolumn chromatography on silica gel, eluting with hexane/Et₂ O (90:10increasing to 80:20), to give the title compound as a yellow solid (8 g,78%). ¹ H NMR (360 MHz, CDCl₃) δ7.48 (2H, m), 7.34-7.23 (3H, m), 7.15(1H, d, J 8.74 Hz), 6.60-6.56 (2H, m), 3.78 (2H, br s), 1.49-1.46 (2H,m), and 1.39-1.35 (2H, m).

DESCRIPTION 7 2-Cyclopropoxy-5-(trifluoromethoxy)benzeneamine

Prepared from the compound of Description 6 according to the method ofDescription 2. ¹ H NMR (360 MHz, CDCl₃) δ7.06 (1H, dd, J 2.8, 6.7 Hz),6.56 (2H, m), 3.83 (2H, br s), 3.74 (1H, m), and 0.79 (4H, m). m/z (ES⁺)234 (M+1).

DESCRIPTION 8 2-Cyclopropoxy-5-(trifluoromethoxy)iodobenzene

An ice-cooled solution of sodium nitrite (3.55 g, 51 mmol) in water (10mL) was added dropwise to a stirred, cooled (0° C.) solution of2-cyclopropoxy-5-(trifluoromethoxy)benzeneamine (Description 7, 4.8 g,20.6 mmol) in aqueous hydrochloric acid (5M, 300 mL), maintaining theinternal temperature at 0° C. The mixture was stirred at 0° C. for 30min., then potassium iodide (8.55 g, 51.5 mmol) in water (10 ml,) wasadded dropwise, maintaining the internal temperature at 0° C. Themixture was stirred at 0° C. for 30 min., then allowed to warm up toroom temperature and stirred until nitrogen evolution ceased. Themixture was extracted with ether, the organic fraction was washed withaqueous sodium thiosulfate (10%), dried (MgSO₄), and the solvent wasevaporated under reduced pressure. The residue was purified by flashcolumn chromatography on silica gel, eluting with hexane/Et₂ O (98:2increasing to 95:5), to give the title compound as a colourless oil(6.23 g, 88%). ¹ H NMR (360 MHz, CDCl₃) δ7.62 (1H, d, J 2.4 Hz), 7.20(1H, dd, J 9.1, 2.4 Hz), 7.15 (1H, d, J 9.1 Hz), 3.80 (1H, m), and 0.83(4H, m).

DESCRIPTION 9 2-Cyclopropoxy-5-(trifluoromethoxy)benzaldehyde

A solution of 2-cyclopropoxy-5-(trifluorometlioxy)iodobenzene(Description 8, 0.344 g, 1 mmol) in toluene (2.5 mL) was degassed withbubbling nitrogen for 10 min. Tetrakis(triphenylphosphine)palladium (0)(15 mg) was added, the mixture was degassed with bubbling nitrogen for afurther 5 min., then carbon monoxide was bubbled through the mixture for10 min. The mixture was warmed to 50° C. and a solution of tributyl tinhydride (0.3 mL, 1.1 mmol) in toluene (5 mL) was added at a rate of 2mL/h. via a syringe pump, maintaining carbon monoxide bubblingthroughout. The mixture was cooled, diluted with ether (20 mL) andaqueous potassium fluoride solution (50%) was added. The mixture wasstirred at room temperature overnight, filtered and the layers wereseparated. The organic layer was dried (MgSO₄), and the solvent wasevaporated under reduced pressure. The residue was purified by flashcolumn chromatography on silica gel, eluting with hexane/Et₂ O (80:20),to give the title compound as a colourless oil. ¹ H NMR (360 MHz, CDCl₃)δ0.86 (4H, m), 3.82-3.9 (1H, m), 7.42 (2H, m), 7.62 (1H, d, J 2.5 Hz),and 10.36 (1H, s).

DESCRIPTION 10 (±)-(2RS)-1-tert-Butoxycarbonyl-2-phenylpiperidin-3-one

Dimethyl sulfoxide (32.0 ml, 35.3 g, 0.45 mol) in dichloromethane (100mL) was added dropwise to a cooled (-70° C.) solution of oxalyl chloride(18.7 mL, 27.5 g, 0.22 mol) in dichloromethane (1000 mL). The mixturewas stirred at -70° C. for 15 min., then(2S,3S)-1-tert-butoxycarbonyl-3-hydroxy-2-phenylpiperidine (prepared bythe method described in European Patent Specification number 0 528495-A; 50 g, 0.18 mol) in dichloromethane (150 mL) was added dropwise.The mixture was stirred at -70° C. for 1 h., then triethylamine (125.8mL, 91.3 g, 0.9 mol) was added slowly. The mixture was stirred at roomtemperature for 1 h., water (250 mL) and aqueous sodium hydrogencarbonate (saturated, 250 mL) were added and the mixture was stirred atroom temperature overnight. The layers were separated and the aqueouslayer was extracted with dichloromethane (2×300 mL). The combinedorganic fractions were washed with brine, dried (MgSO₄) and the solventwas evaporated under reduced pressure. The residue was purified by flashcolumn chromatography on silica gel, eluting with hexane/EtOAc (90:10),to give the title compound as a yellow oil (45.0 g, 91%). ¹ H NMR (250MHz, CDCl₃) δ7.5-7.3 (5H, m), 5.8 (1H, br s), 4.2 (1H, br s), 3.4 (1H,m), 2.6 (2H, m), 2.0 (2H, m), and 1.54 (9H, s).

DESCRIPTION 11(±)-(2R3R,2S3S)-1-(tert-Butoxycarbonyl)-2-phenylpiperidin-3-amine

A solution of hydroxylamine hydrochloride (17 g, 0.24 mol) and sodiumacetate (55.67 g, 0.41 mol) in water (150 mL) was added to a solution of(±)-(2RS)-1-tert-butoxycarbonyl-2-phenylpiperidin-3-one (Description 10,45 g, 0.16 mol) in ethanol (300 mL) and the mixture was stirred at roomtemperature for 1 h. The solvent was evaporated under reduced pressure,water was added and the mixture was extracted with ethyl acetate. Theorganic fraction was washed with brine, dried (MgSO₄) and the solventwas evaporated under reduced pressure. The residue was dissolved inethanol (400 mL) and Raney nickel (50 g) was added. The mixture wasshaken under hydrogen (40 psi) overnight, filtered and the solvent wasevaporated under reduced pressure. The residue was purified by flashcolumn chromatography on silica gel, eluting with CH₂ Cl₂ /MeOH (100:0increasing to 85:15), to give the title compound as a colorless oil(10.9 g, 24%). ¹ H NMR (360 MHz, CDCl₃) δ7.43 (2H, d, J 7.0 Hz), 7.30(3H, m), 5.19 (1H, d, J 6.2 Hz), 4.00 (1H, m), 3.17 (2H, m), 1.90-1.64(4H, m), 1.36 (9H, s), and 1.26 (2H, br s).

COMPOUND C(±)-(2R3R,2S3S)-N-{[2-Cyclopropoxy-5-trifluoromethoxy)phenyl]methyl}-2-phenylpiperidin-3-amineDihydrochloride

2-Cyclopropoxy-5-(trifluoromethoxy)benzaldehyde (Description 9, 55 mg,0.21 mmol) was added to(±)-(2R3R,2S3S)-1-(tert-butoxycarbonyl)-2-phenylpiperidin-3-amine(Description 11, 58 mg, 0.21 mmol), citric acid (89 mg, 0.42 mmol) and 3Å molecular sieves in dry methanol (5 mL) and the mixture was stirred atroom temperature for 1.5 h. Sodium borohydride (30 mg) was added and themixture was stirred at room temperature for 2 h. Ethyl acetate was addedand the mixture was washed with aqueous hydrochloric acid (0.1M, 2×25mL) and brine (25 mL), dried (MgSO₄) and the solvent was evaporatedunder reduced pressure. The residue was dissolved in dichloromethane (3mL), cooled to 0° C. and trifluoroacetic acid (2 mL) was added slowly.The mixture was stirred at room temperature for 1 h., the solvent wasevaporated under reduced pressure and ethyl acetate was added. Themixture was washed with aqueous sodium hydrogen carbonate (saturated,2×25 mL) and brine (25 mL), dried (MgSO₄) and the solvent was evaporatedunder reduced pressure. The residue was purified by flash columnchromatography on silica gel, eluting with CH₂ Cl₂ /MeOH/NH₃ (Aq.)(96:4:0.4). The residue was dissolved in ethanol (2 mL), cooled in iceand ethereal hydrogen chloride (1M, 0.24 mL, 0.24 mmol) was added. Thesolvent was evaporated under reduced pressure and the residue wasrecrystallised from ethanol to give the title compound as a colorlesssolid (20 mg, 20%). m.p. 169-171° C. ¹ H NMR (400 MHz, CD₃ OD) δ0.64(1H, m), 0.80 (3H, m), 1.99 (1H, m), 2.24 (1H, m), 2.46 (2H, m), 3.30(1H, m), 3.64 (1H, m), 3.75 (2H, m), 3.96 (1H, br s), 4.08 (1H, m), 4.95(1H, s), 7.23 (1H, s), 7.31 (1H, d, J 9.0 Hz), 7.37 (1H, d, J 9.0 Hz),7.54 (3H, m), and 7.67 (2H, m). m/z (ES⁺) 407 (M+1).

Particularly preferred NK-1 receptor antagonists of use in the presentinvention are compounds which are potent NK-1 receptor antagonists, i.e.compounds with an NK-1 receptor affinity (IC₅₀) of less than 10 nM,favourably less than 2 nM and preferably less than 1 nM.

The class of orally active, long acting, CNS-penetrant NK-1 receptorantagonists of use in the present invention is identified using acombination of the following assays:

ASSAY 1: NK-1 Receptor binding

NK-1 receptor binding assays are performed in intact Chinese hamsterovary (CHO) cells expressing the human NK-1 receptor using amodification of the assay conditions described by Cascieri et al, J.Pharmacol. Exp. Ther., 1992, 42, 458. Typically, the receptor isexpressed at a level of 3×10⁵ receptors per cell. Cells are grown inmonolayer culture, detached from the plate with enzyme-free dissociationsolution (Speciality Media Inc.), and washed prior to use in the assay.¹²⁵ I-Tyr⁸ -substance P (0.1 nM, 2000 Ci/mmol; New England Nuclear) isincubated in the presence or absence of test compounds (dissolved in 5μl dimethylsulphoxide, DMSO) with 5×10⁴ CHO cells. Ligand binding isperformed in 0.25 ml of 50 mM Tris-HCl, pH 7.5, containing 5 mM MnCl₂,150 mM NaCl, 0.02% bovine serum albumin (Sigma), 50 μg/ml chymostatin(Peninsula), 0.1 nM phenylmethylsulphonyl fluoride, 2 μg/ml pepstatin, 2μg/ml leupeptin and 2.8 μg/ml furoyl saccharine. The incubation proceedsat room temperature until equilibrium is achieved (>40 minutes) and thereceptor-ligand complex is harvested by filtration over GF/C. filterspre-soaked in 0.1% polyethylenimine using a Tomtek 96-well harvester.Non-specific binding is determined using excess substance P (1 μM) andrepresents <10% of total binding.

ASSAY 2: Gerbil Foot-Tapping

CNS-penetrant NK-1 receptor antagonists for use in the present inventioncan be identified by their ability to inhibit foot tapping in gerbilsinduced by anxiogenic agents (such as pentagastrin) or central infusionof NK-1 receptor agonists such as GR73632, or caused by aversivestimulation such as foot shock or single housing, based on the method ofRupniak & Williams, Eur. J. Pharmacol., 1994, 265, 179.

Male or female Mongolian gerbils (35-70 g) are anaesthetised byinhalation of an isoflurane/oxygen mixture to permit exposure of thejugular vein in order to permit administration of test compounds orvehicle in an injection volume of 5 ml/kg i.v. Alternatively, testcompounds may be administered orally or by subcutaneous orintraperitoneal routes. A skin incision is then made in the midline ofthe scalp to expose the skull. An anxiogenic agent (e.g. pentagastrin)or a selective NK-1 receptor agonist (e.g. GR73632 (d Ala[_(L)-Pro⁹,Me-Leu¹⁰ ]-substance P-(7-11)) is infused directly into thecerebral ventricles (e.g. 3 pmol in 5 μl i.c.v., depending on testsubstance) by vertical insertion of a cuffed 27 gauge needle to a depthof 4.5 mm below bregma. The scalp incision is closed and the animalallowed to recover from anaesthesia in a clear perspex observation box(25 cm×20 cm×20 cm). The duration and/or intensity of hind foot tappingis then recorded continuously for approximately 5 minutes.Alternatively, the ability of test compounds to inhibit foot tappingevoked by aversive stimulation, such as foot shock or single housing,may be studied using a similar method of quantification.

ASSAY 3: Ferret Emesis

Individually housed male ferrets (1.0-2.5 kg) are dosed orally by gavagewith test compound. Ten minutes later they are fed with approximately100 g of tinned cat food. At 60 minutes following oral dosing, cisplatin(10 mg/kg) is given i.v. via a jugular vein catheter inserted under abrief period of halothane anaesthesia. The catheter is then removed, thejugular vein ligated and the skin incision closed. The ferrets recoverrapidly from the anaesthetic and are mobile within 10-20 minutes. Theanimals are observed continuously during recovery from the anaestheticand for 4 hours following the cisplatin injection, after which time theanimals are killed humanely. The numbers of retches and vomits occurringduring the 4 hours after cisplatin administration are recorded bytrained observers.

ASSAY 4: Separatioin-Induced Vocalisation

Male and female guinea-pigs pups are housed in family groups with theirmothers and littermates throughout the study. Experiments are commencedafter weaning when the pups are 2 weeks old. Before entering anexperiment, the pups are screened to ensure that a vigorous vocalisationresponse is reproducibly elicited following maternal separation. Thepups are placed individually in an observation cage (55 cm×39 cm×19 cm)in a room physically isolated from the home cage for 15 minutes and theduration of vocalisation during this baseline period is recorded. Onlyanimals which vocalise for longer than 5 minutes are employed for drugchallenge studies (approximately 50% of available pups may fail to reachthis criterion). On test days each pup receives an oral dose or an s.c.or i.p. injection of test compound or vehicle and is then immediatelyreturned to the home cage with its mother and siblings for 30 to 60minutes (or for up to 4 hours following an oral dose, dependent upon theoral pharmacokinetics of the test compound) before social isolation for15 minutes as described above. The duration of vocalisation on drugtreatment days is expressed as a percentage of the pre-treatmentbaseline value for each animal. The same subjects are retested onceweekly for up to 6 weeks. Between 6 and 8 animals receive each testcompound at each dose tested.

As used herein, the term "CNS-penetrant" refers to NK-1 receptorantagonists which are able to inhibit NK-1 receptor antagonist-inducedfoot-tapping in the gerbil as hereinafter defined.

Essentially, hind foot-tapping in the gerbil induced by infusion of theNK-1 receptor agonist, GR73632 (d Ala[_(L) -Pro⁹,Me-Leu¹⁰ ]-substanceP-(7-11)), under anaesthesia, directly into the central ventricles isinhibited when a CNS-penetrant NK-1 receptor antagonist is administeredintravenously immediately prior to GR73632 challenge, wherein hindfoot-tapping over a period of five minutes following recovery from theanaesthesia is inhibited with an ID₅₀ ≦3 mg/kg, and preferably with anID₅₀ ≦1 mg/kg.

In an alternative method, the NK-1 receptor antagonist is administeredorally, 1 hour prior to GR73632 challenge, wherein the foot-tapping overa period of five minutes following recovery from anaesthesia isinhibited with an ID₅₀ ≦30 mg/kg, and preferably with an ID₅₀ ≦10 mg/kg.

CNS-penetrant NK-1 receptor antagonists of use in the present ivnentionare also effective in the attenuation of separation-inducedvocalisations by guinea-pig pups as hereinafter defined.

Essentially, a vocalisation response in guinea-pig pups is induced byisolation from their mothers and littermates, which response isattenuated when a CNS-penetrant NK-1 receptor antagonist is administeredsubcutaneously 30 minutes prior to isolation, wherein vocalisationsduring the first 15 minutes of isolation are attenuated with an ID₅₀ ≦20mg/kg, preferably with an ID₅₀ ≦10 mg/kg, and especially with an ID₅₀ ≦5mg/kg.

In an alternative method, the NK-1 receptor antagonist is administeredorally, 4 hours prior to isolation, wherein vocalisations during thefirst 15 minutes of isolation are attenuated with an ID₅₀ ≦20 mg/kg,preferably with an ID₅₀ ≦10 mg/kg, and especially with an ID₅₀ ≦5 mg/kg.

A suitable selection cascade for NK₁ antagonists of use according to thepresent invention is as follows:

(i) Determine affinity for human NK₁ receptor in radioligand bindingstudies (Assay 1); select compounds with IC₅₀ ≦10 nM, preferably IC₅₀ ≦2nM, especially IC₅₀ ≦1 nM.

(ii) Determine ability of compounds to penetrate CNS by their ability toinhibit foot tapping in gerbils induced by central injection of an NK₁agonist (Assay 2); select compounds that inhibit foot tapping with ID₅₀≦3 mg/kg i.v., and preferably ID₅₀ ≦1 mg/kg i.v. when administeredimmediately prior to central NK₁ agonist challenge, or ID₅₀ ≦30 mg/kgp.o., and preferably ID₅₀ ≦10 mg/kg p.o. 1 hour prior to challenge.

(iii) Determine central duration of action of compounds in gerbil foottapping assay following intravenous administration 24 hours prior tocentral NK₁ agonist challenge; select compounds showing ≦25-fold loss ofpotency compared with ID₅₀ determined in step (ii) above with theproviso that ID₅₀ ≦10 mg/kg i.v., and preferably ≦5 mg/kg i.v. after 24hour pre-treatment.

(iv) Determine oral bioavailability of compounds by pharmacokineticanalysis, activity in gerbil foot tapping assay following oraladministration and/or by ability to inhibit cisplatin-induced emesis inferrets (Assay 3); select compounds with ID₉₀ 23 3 mg/kg p.o., andpreferably ID₉₀ ≦1 mg/kg p.o.

Particularly preferred compounds of use in the present invention areidentified using steps (i) to (iv) followed by step (v):

(v) Determine activity of compounds in assays sensitive to conventionalantipsychotic drugs (inhibition of distress vocalisations in guinea-pigpups (Assay 4)). Select compounds with ID₅₀ ≦20 mg/kg, and preferablyID₅₀ ≦10 mg/kg.

Yet further preferred compounds of use in the present invention may beselected from those compounds which satisfy the NK-1 receptor bindingcriteria of step (i) which, in addition, have ≦5-fold shift in affinitywhen incubated in the presence of human serum albumin (HSA) to shownon-specific protein binding.

One example of a NK-1 receptor antagonist of use in the presentinvention is the compound2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine,the preparation of which is described in International PatentSpecification No. WO 95/16679. In the aforementioned assays, thiscompound has the following activity:

human NK-1 receptor binding: IC₅₀ =0.1 nM

gerbil foot-tapping (5 mins.): ID₅₀ =0.36 mg/kg i.v.

gerbil foot-tapping (24 hrs.): ID₅₀ =0.33 mg/kg i.v.

ferret emesis: ID₉₀ <3 mg/kg p.o.

guinea-pig vocalisation

(4 hr. pre-treatment): ID₅₀ =0.73 mg/kg p.o.

A further example of a NK-1 receptor antagonist of use in the presentinvention is the compound2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine,the preparation of which is described in International PatentSpecification No. WO 95/18124 and U.S. Pat. No. 5,612,337. In theaforementioned assays, this compound has the following activity:

human NK-1 receptor binding: IC₅₀ =0.12 nM

gerbil foot-tapping (5 mins.): ID₅₀ =0.38 mg/kg i.v.

gerbil foot-tapping (24 hrs.): ID₅₀ =2.2 mg/kg i.v.

ferret emesis: ID₉₀ =1 mg/kg p.o.

guinea-pig vocalisation

(4 hr. pre-treatment): ID₅₀ =0.91 mg/kg p.o.

The following example illustrates pharmaceutical compositions accordingto the invention.

EXAMPLE 1 Tablets containing 50-300 mg of NK-1 antagonist

    ______________________________________                                                      Amount mg                                                       ______________________________________                                        NK-1 antagonist 50.0       100.0  300.0                                         Microcrystalline cellulose 80.0 80.0 80.0                                     Modified food corn starch 80.0 80.0 80.0                                      Lactose 189.5 139.5 139.5                                                     Magnesium Stearate 0.5 0.5 0.5                                              ______________________________________                                    

The active ingredient, cellulose, lactose and a portion of the cornstarch are mixed and granulated with 10% corn starch paste. Theresulting granulation is sieved, dried and blended with the remainder ofthe corn starch and the magnesium stearate. The resulting granulation isthen compressed into tablets containing 50 mg, 100 mg and 300 mg of theNK-1 receptor antagonist per tablet.

Pharmaceutical compositions comprising a combination of a NK-1 receptorantagonist and a neuroleptic agent may be prepared with separate activeingredients or with a combination of active ingredients in onecomposition. In such combined preparations, the ratio of the NK-1receptor antagonist and the neuroleptic agent will depend upon thechoice of active ingredients.

EXAMPLE 2 Tablets containing 50-300 mg of NK-1 antagonist and 5-10 mg ofhaloperidol

    ______________________________________                                                    Amount mg                                                         ______________________________________                                        NK-1 antagonist                                                                             50.0   50.0   100.0                                                                              100.0 300.0                                                                              300.0                               haloperidol 5.0 10.0 5.0 10.0 5.0 10.0                                        Microcrystalline cellulose 80.0 80.0 80.0 80.0 80.0 80.0                      Modified food corn starch 80.0 80.0 80.0 80.0 80.0 80.0                       Lactose 184.5 179.5 134.5 129.5 134.5 129.5                                   Magnesium Stearate 0.5 0.5 0.5 0.5 0.5 0.5                                  ______________________________________                                    

The active ingredients, cellulose, lactose and a portion of the cornstarch are mixed and granulated with 10% corn starch paste. Theresulting granulation is sieved, dried and blended with the remainder ofthe corn starch and the magnesium stearate. The resulting granulation isthen compressed into tablets containing 50 mg, 100 mg and 300 mg of theCNS-penetrant NK-1 receptor antagonist per tablet.

What I claim is:
 1. A method for the treatment or prevention of amovement disorder, which method comprises the administration to apatient in need of such treatment of an effective amount of:2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine,or a pharmaceutically acceptable salt thereof.
 2. A method for thetreatment or prevention of a dyskinesia in a patient who isnon-responsive to neuroleptic agents or for whom neuroleptic agents arecontraindicated, which method comprises administration to the patient inneed of such treatment of an effective amount of:2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)-methylmorpholine, or a pharmaceutically acceptablesalt thereof.
 3. A method for the treatment or prevention of anakinetic-rigid disorder or syndrome, which method comprisesadministration to a patient in need of such treatment of:2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine,or a pharmaceutically acceptable salt thereof, and an amount of anantiparkinsonian agent, such that together they give effective relief.4. A method for the treatment or prevention of a dyskinesia, whichmethod comprises administration to a patient in need of such treatmentof an amount of:2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine,or a pharmaceutically acceptable salt thereof, and an amount of aneuroleptic agent, such that together they give effective relief.
 5. Themethod according to claim 1 wherein the movement disorder is selectedfrom akinesias and akinetic-rigid syndromes, dyskinesias andmedication-induced parkinsonian.
 6. The method according to claim 1wherein the movement disorder is Gilles de la Tourette syndrome, and thesymptoms thereof.
 7. The method according to claim 2 wherein thedyskinesia is selected from tremor, chorea, myoclonus, tics, anddystonia.
 8. The method according to claim 4 wherein the dyskinesia isselected from tremor, chorea, myoclonus, tics, and dystonia.
 9. Themethod according to claim 5 wherein the dyskinesia is selected fromtremor, chorea, myoclonus, tics, and dystonia.
 10. The method accordingto claim 3 wherein the akinetic-rigid disorder or syndrome is selectedfrom Parkinson's disease, drug-induced parkinsonism, postencephaliticparkinsonism, progressive supranuclear palsy, multiple system atrophy,corticobasal degeneration, parkinsonian-ALS dementia complex and basalganglia calcification.
 11. The method according to claim 5 wherein theakinetic-rigid disorder or syndrome is selected from Parkinson'sdisease, drug-induced parkinsonism, postencephalitic parkinsonism,progressive supranuclear palsy, multiple system atrophy, corticobasaldegeneration, parkinsonian-ALS dementia complex and basal gangliacalcification.
 12. A pharmaceutical composition comprising2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine,or a pharmaceutically acceptable salt thereof and an antiparkinsonianagent, together with at least one pharmaceutically acceptable carrier orexcipient.
 13. A pharmaceutical composition comprising2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine,or a pharmaceutically acceptable salt thereof and a neuroleptic agent,together with at least one pharmaceutically acceptable carrier orexcipient.